Exact Mass: 451.1849

Exact Mass Matches: 451.1849

Found 22 metabolites which its exact mass value is equals to given mass value 451.1849, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

Doxazosin

1 (4-amino-6,7-Dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine

C23H25N5O5 (451.1856)

Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α₁-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α₁-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

4-Hydroxypropranolol glucuronide

3,4,5-trihydroxy-6-[(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}naphthalen-1-yl)oxy]oxane-2-carboxylic acid

C22H29NO9 (451.1842)

Pseudolycorine-1-O-beta-D-glucoside

C22H29NO9 (451.1842)

doxazosin

Doxazosin, (R)-

C23H25N5O5 (451.1856)

C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3293

Cys Arg Ser Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C15H29N7O7S (451.1849)

Cys Ser Arg Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C15H29N7O7S (451.1849)

Cys Ser Ser Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C15H29N7O7S (451.1849)

Arg Cys Ser Ser

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C15H29N7O7S (451.1849)

4-Hydroxypropranolol glucuronide

C22H29NO9 (451.1842)

Arg Ser Cys Ser

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-hydroxypropanoic acid

C15H29N7O7S (451.1849)

Arg Ser Ser Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-3-sulfanylpropanoic acid

C15H29N7O7S (451.1849)

Ser Cys Arg Ser

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C15H29N7O7S (451.1849)

Ser Cys Ser Arg

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C15H29N7O7S (451.1849)

Ser Arg Cys Ser

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-sulfanylpropanamido]-3-hydroxypropanoic acid

C15H29N7O7S (451.1849)

Ser Arg Ser Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-sulfanylpropanoic acid

C15H29N7O7S (451.1849)

Ser Ser Cys Arg

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-3-sulfanylpropanamido]-5-carbamimidamidopentanoic acid

C15H29N7O7S (451.1849)

Ser Ser Arg Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-sulfanylpropanoic acid

C15H29N7O7S (451.1849)

4-methylumbelliferyl a-l-idopyranosiduronic acid, cyclohexylammonium salt

C22H29NO9 (451.1842)

Dihydrocodeine bitartrate

C22H29NO9 (451.1842)

D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

7-{2-Hydroxy-3-[(naphthalen-1-yl)oxy]propyl}-3-methyl-8-(morpholin-4-yl)-3,7-dihydropurine-2,6-dione

C23H25N5O5 (451.1856)

ST 20:4;O7;Gly

C22H29NO9 (451.1842)

(2r,3s,4s,5r,6s)-2-{[(1r,14s,15s,16s)-4,14-dihydroxy-5-methoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C22H29NO9 (451.1842)